| 1.17 0.01 (0.86%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.61 | 1-year : | 1.82 |
| Resists | First : | 1.38 | Second : | 1.55 |
| Pivot price | 1.2 |
|||
| Supports | First : | 1.1 | Second : | 0.91 |
| MAs | MA(5) : | 1.17 |
MA(20) : | 1.24 |
| MA(100) : | 1.26  |
MA(250) : | 1.55 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 20.2 |
D(3) : | 15.2 |
| RSI | RSI(14): 41.4 |
|||
| 52-week | High : | 3.28 | Low : | 0.53 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ RNXT ] has closed above bottom band by 32.5%. Bollinger Bands are 72.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 12 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.25 - 1.26 | 1.26 - 1.26 |
| Low: | 1.14 - 1.15 | 1.15 - 1.16 |
| Close: | 1.16 - 1.17 | 1.17 - 1.18 |
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
Mon, 15 Apr 2024
RenovoRx Closes $11.1 Million Private Placement, Providing Cash Runway into 2026 - Business Wire
Fri, 08 Mar 2024
RenovoRx Highlights Key Leadership Promotions - Business Wire
Fri, 08 Mar 2024
RenovoRx announces key leadership promotions By Investing.com - Investing.com
Fri, 16 Feb 2024
RNXT Stock Quote Price and Forecast - CNN
Tue, 06 Feb 2024
RenovoRx CEO Issues Letter to Shareholders - Business Wire
Tue, 06 Feb 2024
RenovoRx secures funding for phase III cancer trial - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 17 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 11.7 (%) |
| Held by Institutions | 1.9 (%) |
| Shares Short | 18 (K) |
| Shares Short P.Month | 7 (K) |
| EPS | -1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.29 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -163.2 % |
| Return on Equity (ttm) | -647 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.68 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -10 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -1.19 |
| PEG Ratio | 0 |
| Price to Book value | -4.18 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.93 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|